A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: Improvements in quality of life

International Clinical Psychopharmacology

Volumn 22, Issue 1, 2007, Pages 29-37

  Endicott, Jean ^a   Rajagopalan, Krithika ^a   Minkwitz, Margaret ^a   Macfadden, Wayne ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Bipolar depression; Bipolar disorder; Quality of life; Quetiapine

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LEAST-SQUARES ANALYSIS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SLEEP; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845626145     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097YIC.0b013e32801035a5     Document Type: Article

References (47)

1. Adityanjee, Schulz SC (2002). Clinical use of quetiapine in disease states other then schizophrenia. J Clin Psychiatry 63 (Suppl 13):32-38.
2. Altshuler LL, Gitlin MJ, Mintz J, Leight KL, Frye MA (2002). Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 63:807-811.
3. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington, District of Columbia: American Psychiatric Press.
4. Arnold LM, Witzeman KA, Swank ML, McElroy SL, Keck PE Jr (2000). Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population. J Affect Disord 57:235-239.
5. Bauer MS, Kirk GF, Gavin C, Williford WO (2001). Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J Affect Disord 65:231-241.
6. Berk M, Berk L (2003). Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. Ann Clin Psychiatry 15:217-224.
7. Berlim MT, Mattevi BS, Pavanello DP, Caldieraro MA, Fleck MP (2003). Suicidal ideation and quality of life among adult Brazilian outpatients with depressive disorders. J Nerv Ment Dis 191:193-197.
8. Berlim MT, Pargendler J, Caldieraro MA, Almeida EA, Fleck MP, Joiner TE (2004). Quality of life in unipolar and bipolar depression: are there significant differences? J Nerv Ment Dis 192:792-795.
9. Bishop SL, Walling DP, Dott SG, Folkes CC, Bucy J (1999). Refining quality of life: validating a multidimensional factor measure in the severe mentally ill. Qual Life Res 8:151-160.
10. Bottlender R, Jager M, Strauss A, Moller HJ (2000). Suicidality in bipolar compared to unipolar depressed inpatients. Eur Arch Psychiatry Clin Neurosci 250:257-261.
11. Brady KT, Lydiard RB (1992). Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 12 (Suppl 1):17S-22S.
12. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193-213.
13. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML (2004). Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J Clin Psychiatry 65:1499-1504.
14. Calabrese J, Keck P, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I and II depression. Am J Psychiatry 162:1351-1360.
15. Chen YW, Dilsaver SC (1996). Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorder relative to subjects with other axis I disorders. Biol Psychiatry 39:896-899.
16. Chue P, Kovacs CS (2003). Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 5 (Suppl 2):62-79.
17. Cohen J (1988). Statistical power analysis for the behavioural sciences: 2. New Jersey: Lawrence Erlbaum.
18. Cooke RG, Robb JC, Young LT, Joffe RT (1996). Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-ITEM short form (SF-20). J Affect Disord 39:93-97.
19. Dean BB, Gerner D, Gerner RH (2004). A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 20:139-154.
20. Demyttenaere K, Fruyt JD, Huygens R (2003). Measuring quality of life in depression. Curr Opin Psychiatry 15:89-92.
21. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
22. Goodwin F, Jamison K (1990). Manic-depressive illness. New York: Oxford University Press.
23. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
24. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
25. Kasper S (2003). Issues in the treatment of bipolar disorder. Eur Neuropsychopharmacol 13 (Suppl 2):S37-S42.
26. Katschnig H, Freeman H, Sartorius N, editors (2005). Quality of life in mental disorders. 2nd ed. Chichester: John Wiley & Sons.
27. Lingam R, Scott J (2002). Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105:164-172.
28. MacQueen GM, Young LT, Robb JC, Marriott M, Cooke RG, Joffe RT (2000). Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand 101:374-381.
29. Mayers AG, Van Hooff JC, Baldwin DS (2003). Assessing subjective sleep reports in the first-degree relatives of antidepressant-treated depressed outpatients. Hum Psychopharmacol 18:207-214.
30. McIntyre RS (2002). Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 63 (Suppl 3):15-20.
31. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
32. Namjoshi MA, Buesching DP (2001). A review of the health-related quality of life literature in bipolar disorder. Qual Life Res 10:105-115.
33. Nemeroff CB (2003). Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 64:532-539.
34. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, et al. (2003). Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 64:680-690.
35. Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM, Depakote Comparator Study Group (2003). Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 64:288-294.
36. Riemann D, Voderholzer U, Berger M (2002). Sleep and sleep-wake manipulations in bipolar depression. Neuropsychobiology 45 (Suppl 1):7-12.
37. Sachs GS (2003). Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol 23 (Suppl 1):S2-S8.
38. Sachs GS, Rush AJ (2003). Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals? J Clin Psychiatry 64 (Suppl 6):18-22.
39. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, et al. (2004). Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 26:125-134.
40. Simon GE (2003). Social and economic burden of mood disorders. Biol Psychiatry 54:208-215.
41. Soares JC (2000). Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol 15:183-196.
42. Sussman N (2003). The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 23 (Suppl 1):S21-S26.
43. Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS (2001). Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry 42:190-195.
44. World Health Organization (2001). The world health report 2001. Mental health: new understanding, new hope. Geneva: World Health Organization.
45. Yatham LN (2003). Efficacy of atypical antipsychotics in mood disorders? J Clin Psychopharmacol 23 (Suppl 1):S9-S14.
46. Yatham LN, Lecrubier Y, Fieve RR, Davis KH, Harris SD, Krishnan AA (2004). Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord 6:379-385.
47. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.